Company profile KZIA

Kazia Therapeutics Limited
innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to... treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi Show More
Quarter analysis & expected interestLast update: February 09 2024 12:48:08.

After 39 days of this quarter the interest is at 63.0. Based on that we can calculate that during remaining 52 days it will total up to 147.0.
Kazia Therapeutics expected interest is significantly higher compared to same quarter last year (+104.2%) but similar to previous quarter.

YearQ1Q2Q3Q4
201933
115
248.5% QoQ
109
-5.2% QoQ
135
23.9% QoQ
2020 111
236.4% YoY -17.8% QoQ
112
-2.6% YoY 0.9% QoQ
191
75.2% YoY 70.5% QoQ
258
91.1% YoY 35.1% QoQ
2021 211
90.1% YoY -18.2% QoQ
133
18.8% YoY -37.0% QoQ
120
-37.2% YoY -9.8% QoQ
181
-29.8% YoY 50.8% QoQ
2022 67
-68.2% YoY -63.0% QoQ
0
-100.0% YoY -100.0% QoQ
130
8.3% YoY inf% QoQ
130
-28.2% YoY 0.0% QoQ
2023 72
7.5% YoY -44.6% QoQ
112
inf% YoY 55.6% QoQ
35
-73.1% YoY -68.8% QoQ
106
-18.5% YoY 202.9% QoQ
2024 63
-12.5% YoY -40.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Kazia Therapeutics search interest

There is not enough data for Kazia Therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends Last update: February 09 2024 12:48:11.

The average 5 years interest of Kazia Therapeutics was 9.29 per week.
The last year interest of Kazia Therapeutics compared to the last 5 years has changed by -19.7%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -6.28%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Kazia Therapeutics Limited to provide analysis

Correlation between past revenue and Kazia Therapeutics Limited search interest

There is not enough data for Kazia Therapeutics Limited to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Kazia Therapeutics Limited to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 12:48:16.

After 39 days of this quarter the interest is at 26.0. Based on that we can calculate that during remaining 52 days it will total up to 61.0.
Kazia Therapeutics stock expected interest is significantly lower compared to previous quarter (-67.6%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019124
0
-100.0% QoQ
104
inf% QoQ
0
-100.0% QoQ
2020 25
-79.8% YoY inf% QoQ
191
inf% YoY 664.0% QoQ
107
2.9% YoY -44.0% QoQ
195
inf% YoY 82.2% QoQ
2021 94
276.0% YoY -51.8% QoQ
185
-3.1% YoY 96.8% QoQ
38
-64.5% YoY -79.5% QoQ
0
-100.0% YoY -100.0% QoQ
2022 139
47.9% YoY inf% QoQ
0
-100.0% YoY -100.0% QoQ
69
81.6% YoY inf% QoQ
29
inf% YoY -58.0% QoQ
2023 89
-36.0% YoY 206.9% QoQ
135
inf% YoY 51.7% QoQ
182
163.8% YoY 34.8% QoQ
188
548.3% YoY 3.3% QoQ
2024 26
-70.8% YoY -86.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Kazia Therapeutics stock search interest

There is not enough data for Kazia Therapeutics stock to provide correlation calculation

Analysis of YoY 5Y Google Trends Last update: February 09 2024 12:48:18.

The average 5 years interest of Kazia Therapeutics stock was 7.36 per week.
The last year interest of Kazia Therapeutics stock compared to the last 5 years has changed by 55.43%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 134.91%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 12:48:25.

After 39 days of this quarter the interest is at 31.0. Based on that we can calculate that during remaining 52 days it will total up to 72.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201969
0
-100.0% QoQ
101
inf% QoQ
331
227.7% QoQ
2020 138
100.0% YoY -58.3% QoQ
169
inf% YoY 22.5% QoQ
130
28.7% YoY -23.1% QoQ
194
-41.4% YoY 49.2% QoQ
2021 206
49.3% YoY 6.2% QoQ
47
-72.2% YoY -77.2% QoQ
68
-47.7% YoY 44.7% QoQ
69
-64.4% YoY 1.5% QoQ
2022 119
-42.2% YoY 72.5% QoQ
151
221.3% YoY 26.9% QoQ
94
38.2% YoY -37.7% QoQ
78
13.0% YoY -17.0% QoQ
2023 52
-56.3% YoY -33.3% QoQ
0
-100.0% YoY -100.0% QoQ
27
-71.3% YoY inf% QoQ
74
-5.1% YoY 174.1% QoQ
2024 31
-40.4% YoY -58.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Kazia Therapeutics news search interest

There is not enough data for Kazia Therapeutics news to provide correlation calculation

Analysis of YoY 5Y Google Trends Last update: February 09 2024 12:48:27.

The average 5 years interest of Kazia Therapeutics news was 8.23 per week.
The last year interest of Kazia Therapeutics news compared to the last 5 years has changed by -69.14%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -77.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Paxalisib drug to provide analysis

Correlation between past revenue and Paxalisib drug search interest

There is not enough data for Paxalisib drug to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Paxalisib drug to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for EVT801 drug to provide analysis

Correlation between past revenue and EVT801 drug search interest

There is not enough data for EVT801 drug to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for EVT801 drug to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Kazia Therapeutics CEO to provide analysis

Correlation between past revenue and Kazia Therapeutics CEO search interest

There is not enough data for Kazia Therapeutics CEO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Kazia Therapeutics CEO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Kazia Therapeutics CFO to provide analysis

Correlation between past revenue and Kazia Therapeutics CFO search interest

There is not enough data for Kazia Therapeutics CFO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Kazia Therapeutics CFO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Kazia Therapeutics headquarters to provide analysis

Correlation between past revenue and Kazia Therapeutics headquarters search interest

There is not enough data for Kazia Therapeutics headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Kazia Therapeutics headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for KZIA
Earnings date: 2024-02-28
Company name: Kazia Therapeutics Limited
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-04-15T08:00:00-04:00

PR Newswire
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

2026-04-13T17:05:00-04:00

PR Newswire
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

2026-01-30T08:00:00-05:00

PR Newswire
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

2026-01-28T13:37:46Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Kazia Therapeutics, Maintains $18 Price Target

2026-01-27T08:00:00-05:00

PR Newswire
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

2026-01-08T09:00:00-05:00

PR Newswire
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

2026-01-07T10:32:00-05:00

PR Newswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code

2025-12-22T08:00:00-05:00

PR Newswire
Kazia Therapeutics Regains Full Nasdaq Listing Compliance

2025-12-12T11:19:33Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $18

2025-12-10T08:00:00-05:00

PR Newswire
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

2025-12-02T09:00:00-05:00

PR Newswire
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

2025-11-18T16:15:00-05:00

PR Newswire
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

2025-10-27T07:15:00-04:00

PR Newswire
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

2025-10-07T17:24:42-04:00

SEC
424B3 Form - Prospectus [Rule 424(b)(3)] - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

2025-10-07T17:22:29-04:00

SEC
424B3 Form - Prospectus [Rule 424(b)(3)] - KAZIA THERAPEUTICS LTD (0001075880) (Filer)